Alternative compounded versions of Novo Nordisk’s blockbuster weight-loss and diabetes drugs have hurt its sales, ...

About a dozen lawsuits, citing 2024 studies, allege Ozempic causes a rare eye disorder that leads to irreversible blindness. ...

A grandma of 11 and a New Jersey man have joined the growing chorus of users of the wildly popular weight-loss drugs Ozempic ...

Novo Nordisk's competitive position is strengthening, driven by strong sales growth in Wegovy, Ozempic, and rare diseases.

Novo Nordisk on Wednesday managed the unusual feat of seeing its stock price rise after reducing its earnings outlook. But ...

Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.

Shares of the company, which once boasted of media mogul Oprah Winfrey as one of its top shareholders, slumped 40% in ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

U.S.-listed shares of Novo Nordisk are jumping in premarket trading Wednesday even as the Danish pharmaceutical giant lowered ...

The Danish drugmaker is expanding Wegovy access via telehealth providers like Hims and Ro. But the gap with Eli Lilly is only ...

Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on ...

Novo Nordisk has slashed its full-year revenue and profit forecasts for the first time since launching its blockbuster weight ...